© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 20, 1626-1627,
October 18, 2000
© 2000 Oxford University Press
EDITORIAL |
Dragons 'Round the Fleece Again: STI571 Versus 
1 Acid Glycoprotein
Affiliation of author: Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Correspondence to: Edward A. Sausville, M.D., Ph.D., National Institutes of Health, 6130 Executive Blvd., Suite EPN 8000, Rockville, MD 20852 (e-mail: sausville@nih.gov).
Ovid recounts the story of Jason and his Argonauts (1), who, after dealing with jealous harpies, wandering rocks, spectral armies, and fire-snorting bulls, approach the Golden Fleece only to find it guarded by a sleepless dragon who complicates the ease with which their prize might be grasped. In the current age, we hope to revolutionize cancer therapeutics by defining drug molecules that target the pathophysiologic basis of cancer: activated oncogenes, deregulated tumor suppressor genes, and the ubiquitously relevant processes of angiogenesis and apoptosis. Drugs bound specifically to these or their related targets are the Fleeces of our quest. STI571 is a selective p210bcr-abl oncogene tyrosine kinase inhibitor (2). BCR-ABL-related molecules are etiologic for adult chronic myeloid leukemia (CML) (3) and a fraction of acute lymphoblastic leukemias. Therefore, STI571 treatment of BCR-ABL-expressing neoplasms is prototypic in a way that we hope to emulate by use
REFERENCES
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Barthe, P. Cony-Makhoul, J. V. Melo, J. R. F.-X. Mahon, A. Hochhaus, S. Kreil, A. Corbin, P. La Rosee, T. Lahaye, U. Berger, et al. Roots of Clinical Resistance to STI-571 Cancer Therapy Science, September 21, 2001; 293(5538): 2163a - 2163. [Full Text] [PDF]
|
|